ASX:TLXBiotechs
Should Telix’s AI Prostate Imaging Push and 2026 Revenue Guidance Require Action From Telix (ASX:TLX) Investors?
In late February 2026, Telix Pharmaceuticals Limited announced a research collaboration with University Hospital Essen on the PROMISE-PET registry, aiming to develop AI-based survival prediction models from gallium-68 PSMA-11 PET imaging data alongside new 2026 group revenue guidance of US$950 million to US$970 million.
This combination of AI-enabled prognostic research and quantified revenue expectations underscores how Telix is pairing data-driven innovation in prostate cancer imaging with...